These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

619 related items for PubMed ID: 31175903

  • 1. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma.
    Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY.
    Int J Radiat Oncol Biol Phys; 2019 Oct 01; 105(2):307-318. PubMed ID: 31175903
    [Abstract] [Full Text] [Related]

  • 2. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis.
    Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM.
    Surg Oncol; 2019 Mar 01; 28():228-235. PubMed ID: 30851906
    [Abstract] [Full Text] [Related]

  • 3. Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, Owen D, Cuneo KC, Lawrence TS, Parikh ND, Feng M.
    Int J Radiat Oncol Biol Phys; 2018 Jan 01; 100(1):122-130. PubMed ID: 29066120
    [Abstract] [Full Text] [Related]

  • 4. Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis.
    Jun BG, Kim SG, Kim YD, Cheon GJ, Han KH, Yoo JJ, Kim YS, Jeong SW, Jang JY, Lee SH, Park S, Kim HS.
    PLoS One; 2018 Jan 01; 13(10):e0206381. PubMed ID: 30379885
    [Abstract] [Full Text] [Related]

  • 5. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
    Nabavizadeh N, Jahangiri Y, Rahmani R, Tomozawa Y, Geeratikun Y, Chen Y, Hung A, Degnin C, Farsad K.
    AJR Am J Roentgenol; 2021 Sep 01; 217(3):691-698. PubMed ID: 32997517
    [Abstract] [Full Text] [Related]

  • 6. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P.
    BMC Cancer; 2016 Nov 03; 16(1):834. PubMed ID: 27809890
    [Abstract] [Full Text] [Related]

  • 7. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.
    J Gastroenterol Hepatol; 2016 Feb 03; 31(2):442-9. PubMed ID: 26259976
    [Abstract] [Full Text] [Related]

  • 8. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Sebastian NT, Miller ED, Yang X, Diaz DA, Tan Y, Dowell J, Spain J, Rikabi A, Elliott E, Knopp M, Williams TM.
    Int J Radiat Oncol Biol Phys; 2020 Dec 01; 108(5):1276-1283. PubMed ID: 32712254
    [Abstract] [Full Text] [Related]

  • 9. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
    Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, Kay CS, Heo SJ, Won JY, Seong J.
    J Hepatol; 2020 Jul 01; 73(1):121-129. PubMed ID: 32165253
    [Abstract] [Full Text] [Related]

  • 10. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
    Kibe Y, Takeda A, Tsurugai Y, Eriguchi T.
    Acta Oncol; 2020 Aug 01; 59(8):888-894. PubMed ID: 32216593
    [Abstract] [Full Text] [Related]

  • 11. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.
    Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB.
    BMC Cancer; 2018 Aug 09; 18(1):807. PubMed ID: 30092781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X, Dai Y, Wang DQ, Zhang L, Sui CG, Meng FD, Jiang SY, Liu YP, Jiang YH.
    Drug Des Devel Ther; 2015 Aug 09; 9():4431-40. PubMed ID: 26309396
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
    Shui Y, Yu W, Ren X, Guo Y, Xu J, Ma T, Zhang B, Wu J, Li Q, Hu Q, Shen L, Bai X, Liang T, Wei Q.
    Radiat Oncol; 2018 Sep 25; 13(1):188. PubMed ID: 30253783
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.